TheBrief.Health

FDA recalled six lots of compounded glutathione, Myers’ Cocktail, and Tri-Immune Boost injections over elevated endotoxin levels, prompting quarantine, exposure tracing, and clinical assessment.

A 2026 network meta-analysis found SGLT2 inhibitors more consistently reduced heart failure hospitalization, while mortality comparisons remained uncertain and empagliflozin’s arrhythmia signal requires confirmation.

FDA approved tiratricol for peripheral thyrotoxicosis in MCT8 deficiency, targeting excess T3 and cardiovascular effects without establishing reversal of neurological disability.

WHO’s pediatric sickle cell initiative emphasizes implementation, linking early screening, preventive treatment, referral, medicine access, and follow-up to improve equitable care for children.

Baxter recalled one cefazolin in dextrose injection lot over cardboard particles, prompting hospitals to quarantine affected inventory, maintain perioperative antibiotic coverage, and assess potential exposures.

ACHIEVE-5 found oral orforglipron added to titrated insulin glargine improved HbA1c and weight without increasing hypoglycemia, though numerical effect sizes and detailed safety findings remain important.

A randomized pediatric trial found ecopipam reduced Tourette syndrome tic severity versus placebo, supporting further investigation while long-term safety, comparative effectiveness, and FDA approval remain unresolved.

FDA classified the Luna G3 APAP firmware recall as Class I, urging clinics and suppliers to verify affected devices, coordinate corrections, and prevent therapy interruptions.

FDA approved camizestrant for eligible ESR1-mutated advanced breast cancer, enabling mutation-guided endocrine switching before radiographic progression while continuing CDK4/6 inhibitor therapy.

FDA classified Halyard IV START KIT NONSTERILE as Class I, prompting urgent inventory isolation, identifier verification, workflow protection, alternative supplies, and risk-based review of prior use.

FDA classified PiCardia’s ShortCut transfemoral catheter action as a Class 2 recall, prompting inventory checks, procedure planning updates, traceability, and review of prior device use.

FDA accelerated approval makes sevabertinib available for previously treated advanced nonsquamous NSCLC with qualifying HER2 mutations, emphasizing precise molecular testing and avoiding broad HER2 eligibility.

FDA approved lirafugratinib for previously treated advanced FGFR2-rearranged cholangiocarcinoma, making validated molecular testing essential for identifying eligible patients and guiding targeted treatment decisions after progression.

American Regent recalled a papaverine injection lot after particulate matter findings, prompting quarantine, inventory tracing, exposure assessment, symptom monitoring, and urgent evaluation for postexposure events.

FDA granted accelerated approval to sevabertinib for select HER2-mutated non-squamous NSCLC, requiring precise molecular eligibility while confirmatory studies establish clinical benefit.

ASTRUM-006 found serplulimab plus perioperative SOX improved event-free survival in PD-L1-selected resectable gastric or gastroesophageal junction cancer, supporting biomarker-guided investigation.

Randomized evidence found fecal microbiota transplantation more effective than vancomycin or fidaxomicin for recurrent C. difficile infection, supporting microbiota restoration after repeated antibiotic failures.

The 2026 universal heart failure definition standardizes diagnosis and documentation across care settings, potentially affecting referrals, coding, research criteria, and local implementation workflows.

ITACS evaluates preoperative intravenous iron for anemia before cardiac surgery, but its supplied citation lacks results needed to determine effects on transfusion, recovery, or safety.

Endocrine Society guidance discourages routine brain MRI for selected children with central precocious puberty, emphasizing neurologic assessment and individualized imaging when concerning findings are present.

WHO urges stronger safety monitoring as GLP-1 use expands for weight loss, emphasizing appropriate prescribing, product verification, structured follow-up, and adverse-event reporting.

FDA reported 184 serious injuries linked to specified esophageal pH capsule delivery devices, prompting inventory review, procedural safeguards, traceability, and explicit postprocedure follow-up.

WHO’s new filovirus guidance unifies Ebola and Marburg care, emphasizing rapid triage, supportive treatment, infection prevention, staff protection, diagnostics, and coordinated outbreak response.